Manufacturing Facilities

Home > Business Development > Manufacturing Facilities

The wide offer of high-quality product enables Hanmi to reach favorable business results. To keep this trend in the future, Hanmi has recently completed two plants investing USD 93 million in order to implement new technological upgrades and to constantly supply good qualified products. Hanmi is planning to takeoff as a Global Pharmaceutical Company with newly built plants since they achieved as no.1 in the Korean market and is currently looking for partners to collaborate in the field of Contract Manufacturing for innovative drug APIs, key intermediates, Cephalosporin APIs, finished products, and both oral and injectables. In order to review Hanmi’s plants please follow the instructions for our newly built plants, which will bring you successful and excellent Contract Manufacturing Service.

Hanmi Celpha PlantAPI Plant of Hanmi Fine Chemical

API Plant of Hanmi Fine Chemical

Hanmi Cepha Plant is the plant for the production of Cephalosporine finished dosage dedicated to both oral solid and powder parenteral injections. Its capacity will be about 30 million powder inAPI Plant is the faclility for the production of General API products which various synthetic technologies are applied to. All the construction and installation works were completed in June of 2007.
The API Plant was built in accordance with the latest technical solutions and the Good Manufacturing Practice guidelines, as well as in accordance with other safety standards for the protection of people and the environment.
      1
      2
      3
      4
      5
  • API Plant in Shihung, Korea

    History of Hanmi's API manufacturing Site

  • 2009's

    Jul, 2009
    Inspected & approved by Australian TGA

  • 2008's

    Dec, 2008
    Inspected by UK MHRA and Granted EU GMP certificate

  • 2007's

    Nov, 2007
    Inspected by German BSG and Granted EU GMP Certificate
    Jun, 2007
    completed new plant for General API's

  • 2006's

    Mar, 2006
    Inspected by UK MHRA and Granted EU GMP Certificate
    Apr, 2006
    Inspected by US FDA and approved

  • 2004's

    Dec, 2004
    Submitted US DMF of Sterile Ceftraxone Sodium

  • 2003's

    Sep, 2003
    CEP Granted to Sterile Ceftazidime & Cefixime
    Jun, 2003
    Inspected by German BUG in Hamburg and EU GMP approved

  • 2000's

    Sep, 2000
    Inspected by UK MCA and EU GMP approved

  • 1999's

    May, 1999
    KGMP Certificate Granted by KFDA

  • 1998's

    Dec, 1998
    CEP Granted to Sterile Ceftriaxone Sodium
    Sep, 1998
    CEP Granted to Sterile Cefotaxime Sodium

  • 1993's

    Jan, 1993
    Moved to Shiwha Plant

  • 1989's

    Feb, 1989
    Transferred New Process Technology of Ceftriaxone Sodium to Hoffman La Roche, Switzerland

  • 1984's

    Feb, 1984
    Founded by Joint Investment b/w Hanmi Pharm. & KTFC

Major API Products List

Plant 1
Sterile Cephalosporin
  • Sterile Ceftriaxone Sodium
  • Sterile Sefotaxime Sodium
  • Sterile Ceftazidime
  • Sterile Cefotiam Hydrochloride
  • Sterile Ceftizoxime Sodium
Oral Cephalosporin
  • Cefixime
  • Cefpodoxime Proxetil
  • Cefdinir
  • Cefprozil
Plant 2
General APIs
  • Amlodipine
  • Rebamipide
  • Clopidogrel
  • Losartan
  • Pioglitazone
  • Itraconazole
  • Sibutramine
  • S-omeprazole
  • Atorvastatin